Serum von Willebrand factor for early diagnosis of lung adenocarcinoma in patients with type 2 diabetes mellitus

Table 1 Demographic characteristics and laboratory results of the subjects (mean ± SD)

	T2DM + AIS (n = 43)	T2DM (n = 43)	AIS (n = 43)	Control (n = 43)
Male/Female	21/22	21/22	21/22	21/22
Age, yr	58 ± 8	57 ± 10	59 ± 11	58 ± 10
BMI, kg/m2	23.32 ± 3.59	24.10 ± 3.74	23.43 ± 3.74	23.20 ± 3.18
IGF-1, ng/mL	131.4 ± 50.45	111.0 ± 30.21a	106.6 ± 35.80b	56.93 ± 24.65bde
IGFBP3, μg/mL	3.48 ± 0.78	3.53 ± 1.09	3.13 ± 1.33	1.71 ± 0.79bde
vWF, ng/mL	9.18 ± 0.53	5.33 ± 0.24b	4.86 ± 0.15b	2.69 ± 0.44bde
HbA1c, %	7.65 ± 1.79	9.75 ± 2.51b	5.05 ± 0.52bd	5.29 ± 0.52bd
TC, mmol/L	4.33 ± 0.99	4.72 ± 1.38	4.75 ± 0.85	4.91 ± 0.87b
TG, mmol/L	1.48 ± 0.73	1.55 ± 0.81	1.38 ± 0.54	1.48 ± 0.81
HDL-C, mmol/L	1.14 ± 0.38	1.19 ± 0.33	1.32 ± 0.27	1.38 ± 0.32ac
LDL-C, mmol/L	2.48 ± 0.81	2.65 ± 1.17	2.74 ± 0.64	2.81 ± 0.75
FBG, mmol/ L	7.36 ± 2.66	7.14 ± 4.09	5.13 ± 0.52bd	5.17 ± 1.19bd
FINS, mU/L	9.94 ± 8.69	14.43 ± 7.60b	15.27 ± 2.29b	15.22 ± 2.09b
HOMA-IR	2.97 ± 2.44	4.74 ± 3.82b	3.46 ± 0.62	3.52 ± 1.29

^aP < 0.05,

^bP < 0.01 vs T2DM + AIS group;

^cP < 0.05,

^dP < 0.01 vs T2DM group; ^eP < 0.05,

^eP < 0.01 vs AIS group. T2DM: Type 2 diabetes mellitus; AIS: Adenocarcinoma in situ; BMI: Body mass index; IGF-1: Insulin-like growth factor 1; IGFBP3: Insulin-like growth factor binding protein 3; vWF: von Willebrand factor; HbAlc: Glycosylated hemoglobin; TC: Total cholesterol; TG: Triglyceride; HDL-C: High density lipoprotein cholesterol; LDL-C: Low density lipoprotein cholesterol; FPG: Fasting plasma glucose; FINS: Fasting insulin; HOMA-IR: Homeostatic model assessment-estimated insulin resistance.